Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Camurati-Engelmann Syndrome × Trabedersen × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Neoplasms 1 Lung Neoplasms 1 Glioblastoma 1 Carcinoma, Non-Small-Cell Lung 1 Camurati-Engelmann Syndrome 1 Brain Neoplasms 1 Astrocytoma 1

Interventions

fresolimumab 1 bintrafusp alfa protein, human 1 ascrinvacumab 1 Trabedersen 1 Temozolomide 1 Sorafenib 1 Radiotherapy 1 Losartan 1 Lomustine 1 LY-2157299 1 Drug Delivery Systems 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00431561 2013-12-03

Phase IIb Clinical Trial With TGF-β2 Antisense Compound AP 12009 for Recurrent or Refractory High-grade Glioma

Isarna Therapeutics GmbH

Phase 2 Completed

Astrocytoma, Brain Neoplasms, Camurati-Engelmann Syndrome, Glioblastoma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡